Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2025-04-08 Share Issue/Capital Cha…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
20250408 Sequana Medical - GEM Capital Increases -- Press Release (ENG).pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled "SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES" and details a specific increase in share capital and the number of issued shares resulting from a contribution in kind related to a share subscription facility agreement. It explicitly mentions the change in capital structure and the issuance of new shares. This directly relates to changes in the company's capital structure and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It is a specific announcement about capital structure change.
2025-04-08 English
20250408 Sequana Medical - GEM Capital Increases -- Press Release (NL).pdf
Share Issue/Capital Change Classification · 98% confidence The document is titled with a date (8 april 2025) and explicitly states it is a press release ('PERSBERICHT GEREGLEMENTEERDE INFORMATIE'). The content details a capital increase ('kapitaal van de Vennootschap werd verhoogd') due to an in-kind contribution related to a financing facility (GEM Global Yield LLC SCS). This involves the issuance of new shares and changes to the total number of outstanding shares. This type of announcement, concerning changes in capital structure, share issuance, and financing agreements, directly aligns with the definition of a Capital/Financing Update (CAP). Although it involves share issuance, the primary focus is the execution of the financing agreement and the resulting capital change, making CAP more specific than SHA (Share Issue/Capital Change) which is broader, or RNS (Regulatory Filings) which is the fallback. Given the specific nature of the capital change driven by a financing arrangement, CAP is the most appropriate code.
2025-04-08 Dutch
20250318 Press Release_FYR 2024_ENG.pdf
Earnings Release Classification · 100% confidence The document is a comprehensive announcement of the company's 2024 full-year financial results, business updates, and 2025 outlook. It includes detailed sections on operational highlights, clinical trial results, financing activities, and board changes. While it contains financial highlights, it is structured as a formal management communication regarding the company's performance and strategic direction for the fiscal year, which aligns with the definition of a Management Report (MDA). FY 2024
2025-03-18 English
20250318 Press Release_FYR 2024_NL.pdf
Earnings Release Classification · 95% confidence The document is a press release titled 'Sequana Medical rapporteert jaarresultaten 2024 en vooruitzichten 2025'. It provides a summary of financial highlights, operational updates, and strategic outlook for the fiscal year 2024. While it contains financial data, it is structured as a corporate announcement (press release) rather than a full statutory Annual Report (10-K) or a formal Interim/Quarterly Report (IR). According to the 'Menu vs Meal' rule, this document serves as an initial announcement of results rather than the full audited financial report itself. Therefore, it is classified as an Earnings Release (ER). FY 2024
2025-03-18 Dutch
13 -- Annual Report 2024 ENG-vF.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2024' and contains a comprehensive table of contents covering business strategy, corporate governance, remuneration reports, and full financial statements (Income Statement, Balance Sheet, Cash Flows, etc.). It is a substantial document (over 700,000 characters) that provides a detailed account of the company's yearly performance, strategy, and financial position, fitting the definition of a 10-K/Annual Report. FY 2024
2025-03-18 English
13 -- Annual Report 2024 NL-vF.pdf
Annual Report Classification · 100% confidence The document is titled 'JAARVERSLAG 2024' (Annual Report 2024) and contains a comprehensive table of contents covering strategy, business achievements, corporate governance, and consolidated financial statements (balance sheet, income statement, cash flow). It provides detailed financial and operational information for the fiscal year 2024, which aligns with the definition of an Annual Report (10-K). FY 2024
2025-03-18 Dutch

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.